Setting 
My Cart
Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 481-490 of 9364

Page
per page
  1. Galanthamine HBr
    A1745 Galanthamine HBr
    Summary: Acetylcholinesterase inhibitor
      insoluble in ETOH; ≥36.9 mg/mL
  2. Odanacatib (MK-0822)
    A2487 Odanacatib (MK-0822)
    Target: Cathepsins
    Summary: Cathepsin K,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥17.7 mg/mL
  3. NVP-AEW541
    A2278 NVP-AEW541
    Target: Insulin Receptor
    Summary: IGF-IR inhibitor, novel, potent and selective
      ≥22 mg/mL
  4. Brivanib Alaninate (BMS-582664)
    A2633 Brivanib Alaninate (BMS-582664)
    Summary: VEGFR2 inhibitor,ATP-competitive
      ≥22.05 mg/mL
  5. Epothilone A
    A1623 Epothilone A
    Summary: Microtubule stabilizing macrolide
      insoluble in H2O; ≥17.45 mg/mL
  6. PIK-90
    A2764 PIK-90
    Summary: PI3K inhibitor,potent selective
      insoluble in DMSO
  7. PIK-75 HCl
    A2080 PIK-75 HCl
    Summary: Inhibitor of PI3K isoform p110α
      insoluble in H2O; insoluble in EtOH; ≥8.15 mg/mL
  8. Canertinib (CI-1033)
    A1845 Canertinib (CI-1033)
    Summary: HER family tyrosine kinase inhibitor
  9. Zoledronic Acid
    A1352 Zoledronic Acid
    Target: Farnesyl Diphosphate Synthases
    Summary: Potent nitrogen-containing bisphosphonates
      insoluble in DMSO; insoluble in H2O; insoluble in EtOH
  10. IC-87114
    A2065 IC-87114
    Summary: PI3Kδ inhibitor

Items 481-490 of 9364

Page
per page